Unicycive Therapeutics Inc (Nasdaq:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced on Monday that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of 28 June 2025. If approved, OLC could offer a more convenient treatment option for CKD patients with hyperphosphatemia, requiring fewer pills per dose and easier administration.
The NDA submission is based on data from clinical and preclinical studies, as well as chemistry, manufacturing and controls data.
Unicycive is preparing for a potential commercial launch of OLC in the second half of 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval